Home/Eagle Pharmaceuticals/Daniel O’Connor

DO

Daniel O’Connor

Chief Strategy Officer & Head of Corporate Development

Eagle Pharmaceuticals

Therapeutic Areas

Critical Care Oncology

Eagle Pharmaceuticals Pipeline

Drug	Indication	Phase
BARHEMSYS® (amisulpride) injection	Postoperative nausea and vomiting (PONV)	Approved/Commercial
BYFAVO® (remimazolam) for injection	Induction and maintenance of procedural sedation	Approved/Commercial
First-in-class NCE Pipeline	Oncology and Critical Care	Not Specified

Leadership Team at Eagle Pharmaceuticals

Chief Executive Officer & Chairman of the Board

Christopher Krawtschuk

Chief Financial Officer

Head of Commercial for Acute Care/Hospital

Jennifer Simpson, PhD

Lead Independent Director, Board Member

Richard A. Edlin, J.D.

Robert L. Glenning

Luciana Borio, MD

View full Eagle Pharmaceuticals profile